CN1227231C - 作为抗糖尿病药的醚和酰胺类化合物及制备方法 - Google Patents

作为抗糖尿病药的醚和酰胺类化合物及制备方法 Download PDF

Info

Publication number
CN1227231C
CN1227231C CNB011047011A CN01104701A CN1227231C CN 1227231 C CN1227231 C CN 1227231C CN B011047011 A CNB011047011 A CN B011047011A CN 01104701 A CN01104701 A CN 01104701A CN 1227231 C CN1227231 C CN 1227231C
Authority
CN
China
Prior art keywords
compound
general formula
same meaning
compounds
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB011047011A
Other languages
English (en)
Chinese (zh)
Other versions
CN1315320A (zh
Inventor
冨山刚
冨山格
冨山泰
黑岩敬子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kotobuki Seiyaku Co Ltd
Original Assignee
Kotobuki Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kotobuki Seiyaku Co Ltd filed Critical Kotobuki Seiyaku Co Ltd
Publication of CN1315320A publication Critical patent/CN1315320A/zh
Application granted granted Critical
Publication of CN1227231C publication Critical patent/CN1227231C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CNB011047011A 2000-01-11 2001-01-11 作为抗糖尿病药的醚和酰胺类化合物及制备方法 Expired - Fee Related CN1227231C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP6106/00 2000-01-11
JP2000006106 2000-01-11
JP2000356303A JP4316787B2 (ja) 2000-01-11 2000-11-22 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
JP356303/00 2000-11-22

Publications (2)

Publication Number Publication Date
CN1315320A CN1315320A (zh) 2001-10-03
CN1227231C true CN1227231C (zh) 2005-11-16

Family

ID=26583525

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB011047011A Expired - Fee Related CN1227231C (zh) 2000-01-11 2001-01-11 作为抗糖尿病药的醚和酰胺类化合物及制备方法

Country Status (9)

Country Link
US (1) US6414001B2 (https=)
JP (1) JP4316787B2 (https=)
KR (1) KR20010070442A (https=)
CN (1) CN1227231C (https=)
DE (1) DE10100772B4 (https=)
ES (1) ES2187261B2 (https=)
FR (1) FR2804681B1 (https=)
GB (1) GB2359082B (https=)
IT (1) ITMI20010042A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2418104A1 (en) 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU2001284660A1 (en) 2000-08-23 2002-03-04 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
JP2004509084A (ja) 2000-08-23 2004-03-25 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用
US7009057B2 (en) * 2001-04-26 2006-03-07 Zentiva A.S. Method for obtaining pioglitazone as an antidiabetic agent
HRP20031002A2 (en) 2001-06-07 2004-06-30 Lilly Co Eli Modulators of peroxisome proliferator activated receptors (ppar)
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
TWI281916B (en) 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US20080045706A1 (en) * 2002-12-31 2008-02-21 Flynn Daniel L Anti-inflammatory medicaments
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
ES2297382T3 (es) 2003-02-14 2008-05-01 Eli Lilly And Company Derivados de sulfonamida como moduladores de ppar.
US7348453B2 (en) * 2003-09-04 2008-03-25 Mirus Bio Corporation Labile linkage for compound delivery to a cell
JP4175291B2 (ja) * 2004-05-12 2008-11-05 トヨタ自動車株式会社 車両の減速制御装置
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PL1650186T3 (pl) * 2004-10-22 2008-11-28 Bioprojet Soc Civ Nowe pochodne kwasów dikarboksylowych
CN101735048A (zh) * 2008-11-05 2010-06-16 上海慈瑞医药科技有限公司 具胰岛素增敏活性的水杨酸类化合物及其制备方法
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
US9388179B2 (en) 2012-10-26 2016-07-12 Merck Sharp & Dohme Corp. N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
CN112028833B (zh) * 2020-09-25 2022-07-05 西南大学 对氨基水杨酸唑类衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008652A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5239080A (en) * 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
WO1992003425A1 (en) * 1990-08-23 1992-03-05 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
TW245716B (https=) * 1992-12-28 1995-04-21 Takeda Pharm Industry Co
TW268952B (https=) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CN1233241A (zh) * 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
AU7052200A (en) * 1999-08-27 2001-03-26 Eli Lilly And Company Hypoglycemic sulfonyl pyrazolones and pyrazolines
US6617343B1 (en) * 1999-08-27 2003-09-09 Eli Lilly And Company Hypoglycemic N,N-arylsulfonylglycine compounds

Also Published As

Publication number Publication date
DE10100772B4 (de) 2005-09-22
ES2187261B2 (es) 2004-07-16
JP4316787B2 (ja) 2009-08-19
US20010008898A1 (en) 2001-07-19
GB2359082B (en) 2004-09-29
JP2001261662A (ja) 2001-09-26
GB2359082A (en) 2001-08-15
ES2187261A1 (es) 2003-05-16
CN1315320A (zh) 2001-10-03
FR2804681B1 (fr) 2004-06-25
FR2804681A1 (fr) 2001-08-10
DE10100772A1 (de) 2001-07-19
KR20010070442A (ko) 2001-07-25
ITMI20010042A1 (it) 2002-07-11
US6414001B2 (en) 2002-07-02
GB0100433D0 (en) 2001-02-21

Similar Documents

Publication Publication Date Title
CN1227231C (zh) 作为抗糖尿病药的醚和酰胺类化合物及制备方法
CN1304382C (zh) 用于治疗炎性、免疫或心血管疾病的新的p2x7受体拮抗剂
CN1110493C (zh) 氨基噻吩羧基酰胺及其作为磷酸二酯酶抑制剂的用途
CN1024667C (zh) 取代的氨甲基四氢化萘和取化氨甲基氢化苯并吡喃及其盐制备方法
CN1136213C (zh) 新的苯并噻吩、苯并呋喃和吲哚化合物、其制备方法和含有它们的药物组合物
CN1671659A (zh) 新的取代吲哚
CN1095716A (zh) 具有极好的降血糖活性的新颖化合物
CN1200935C (zh) 制备苯并呋喃或苯并噻吩类型化合物的方法
CN1596247A (zh) 用作人11cby受体拮抗剂的内酰胺衍生物
CN1040986A (zh) 环烷基取代的戊二酰胺衍生物的制备
CN101080391A (zh) 2－吡啶基乙基羧酰胺衍生物的制备方法
CN1033325C (zh) 抗炎异羟肟酸和n-羟基脲的制备方法
CN1053064A (zh) 杂环衍生物制法
CN87104319A (zh) 苯并吡喃衍生物
CN1206212C (zh) 新的三－取代的苯基衍生物和类似物
CN1211374C (zh) 新的杂环衍生物、其制备方法和包含它们的药物组合物
CN1516695A (zh) 用作抗病毒剂的芳基磺酰胺类化合物
CN1115576A (zh) 具有细胞浆磷脂酶a2抑制活性的噁唑啉酮衍生物
HK1044534A1 (en) Pyridazin-3-one derivatives and medicines containing the same
CN1590379A (zh) 新的杂环肟化合物、它们的制备方法和含有它们的药物组合物
CN1805947A (zh) 合成2－羟基－n , n－二甲基－3－[[2－[[1 ( r )－(5－甲基－2－呋喃基)丙基]氨基]－3 , 4－二氧代－1－环丁烯－1－基]氨基] 苯甲酰胺
CN1708491A (zh) N－苯并间二氧杂环戊烯基、n－苯并二噁烷基和n－苯并二氧杂䓬基芳基甲酰胺衍生物以及包含它们的药物组合物
CN1852907A (zh) 2－氨基－5－苯甲酰基噻唑npy拮抗剂
HK1049169A1 (en) Substituted 4-benzylaminoquinolines, process for their preparation, pharmaceuticals containing these compounds and use thereof
CN1173977C (zh) 制备噻吩并嘧啶衍生物的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051116

Termination date: 20100211